Dyne Therapeutics/DYN

$25.85

-5.58%
-
1D1W1MYTD1YMAX

About Dyne Therapeutics

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Ticker

DYN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Cox

Employees

141

Headquarters

Waltham, United States

DYN Metrics

BasicAdvanced
$2.23B
Market cap
-
P/E ratio
-$3.94
EPS
0.98
Beta
-
Dividend rate
$2.23B
0.98171
$30.27
$6.40
1.41M
2.532
-100.1%
-137.31%
-120.31%
17.405
24.402
-21.75%

What the Analysts think about DYN

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
46.03% upside
High $56.00
Low $20.00
$25.85
Current price
$37.75
Average price target

DYN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-66.6M
10.63%
Profit margin
0%
-

DYN Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 18.91%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.78
-$1.08
-$0.99
-$1.09
-
Expected
-$0.77
-$0.81
-$0.83
-$0.92
-$0.80
Surprise
1.46%
33.75%
18.92%
18.91%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Dyne Therapeutics stock?

Dyne Therapeutics (DYN) has a market cap of $2.23B as of April 14, 2024.

What is the P/E ratio for Dyne Therapeutics stock?

The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of April 14, 2024.

Does Dyne Therapeutics stock pay dividends?

No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Dyne Therapeutics dividend payment date?

Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.

What is the beta indicator for Dyne Therapeutics?

Dyne Therapeutics (DYN) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Dyne Therapeutics stock price target?

The target price for Dyne Therapeutics (DYN) stock is $37.75, which is 46.03% above the current price of $25.85. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Dyne Therapeutics stock

Buy or sell Dyne Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing